Peculiarities of L-DOPA treatment of Parkinson’s disease

@article{Kostrzewa2005PeculiaritiesOL,
  title={Peculiarities of L-DOPA treatment of Parkinson’s disease},
  author={Richard M. Kostrzewa and P. Nowak and John P. Kostrzewa and Rose Anna Kostrzewa and Ryszard Brus},
  journal={Amino Acids},
  year={2005},
  volume={28},
  pages={157-164}
}
Summary.L-Dihydroxyphenylalanine (L-DOPA), the anti-parkinsonian drug affording the greatest symptomatic relief of parkinsonian symptoms, is still misunderstood in terms of its neurotoxic potential and the mechanism by which generated dopamine (DA) is able to exert an effect despite the absence of DA innervation of target sites in basal ganglia. This review summaries important aspects and new developments on these themes. On the basis of L-DOPA therapy in animal models of Parkinson’s disease… Expand
Expanding the repertoire of L-DOPA’s actions: A comprehensive review of its functional neurochemistry
TLDR
L-DOPA exerts a surprisingly complex pattern of neurochemical effects of much greater scope that mere striatal transformation into DA in spared dopaminergic neurons, and may exert intrinsic receptor-mediated actions independently of DA neurotransmission and can be processed into bioactive metabolites. Expand
Molecular Effects of L-dopa Therapy in Parkinson’s Disease
TLDR
Administration of vitamins B6, B12, and folates along with an effective therapy with antioxidants and/or anti-inflammatory drugs at an early stage of PD might contribute to improvement in the quality of the life of patients with PD and to slowing down or stopping the progression of the disease. Expand
Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease.
TLDR
It seems reasonable to suggest that L-DOPA could potentially produce dopaminergic neurotoxicity, as the striatal levels of dopamine were reduced after MPTP or L- DOPA, with an increased turnover only for the MPTP group. Expand
Unpredictable rotational responses to L-dopa in the rat model of Parkinson's disease: the role of L-dopa pharmacokinetics and striatal dopamine depletion.
TLDR
It was found that variation in plasma levels of L-dopa as well as the administration route explains a part of the variability in rotation in 6-OHDA rats. Expand
Effect of ketanserin and amphetamine on nigrostriatal neurotransmission and reactive oxygen species in Parkinsonian rats. In vivo microdialysis study.
TLDR
The findings from the current study showed that the use of 5-HT(2A/2C) receptor antagonists in Parkinson's disease does not impend the neostriatal neuropil to be damaged by these drugs. Expand
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation
TLDR
The conclusion is that the cause of levodopa-induced dyskinesia remains to be fully elucidated and that new approaches to treatment through non-dopaminergic mechanisms are required to control the onset and expression of involuntary movements. Expand
Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's disease
  • R. Cools
  • Medicine, Psychology
  • Neuroscience & Biobehavioral Reviews
  • 2006
TLDR
It is suggested that beneficial or detrimental effects of L-DOPA are observed depending on task demands and basal dopamine levels in distinct parts of the striatum, which has substantial implications for the understanding and treatment development of cognitive abnormalities in Parkinson's disease and normal health. Expand
Acute l-DOPA Effect on Hydroxyl Radical- and DOPAC-Levels in Striatal Microdialysates of Parkinsonian Rats
TLDR
L-DOPA, an effective drug in ameliorating PD symptoms, did not acutely pose a risk for HO• generation in parkinsonian rats and is not likely to generate reactive oxygen species in humans nor is l-DPA likely to accelerate PD in humans. Expand
Dopamine D2 agonists, bromocriptine and quinpirole, increase MPP+-induced toxicity in PC12 cells
Dopaminergic cell loss in the mesencephalic substantia nigra is the hallmark of Parkinson’s disease and may be associated with abnormal oxidative metabolic activity. However, the delicate balanceExpand
Striatal extracellular dopamine levels and behavioural reversal in MPTP-lesioned mice
TLDR
Interestingly, only 5 mg/kg L-DOPA normalized DA levels to 56% of controls showing that only a minor increase in DA levels is sufficient to yield motor recovery. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 48 REFERENCES
Effects ofl-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats
In vivo microdialysis was used to examine the effect of L-3,4-dihydroxyphenylalanine (L-DOPA) administration upon dopamine (DA) in extracellular fluid both in intact striatum and in striatum of ratsExpand
Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
TLDR
The data suggests that chronic L-dopa/carbidopa treatment reverses the increased dopaminergic activity and D1 receptor functional supersensitivity seen after 6-hydroxydopamine lesions, and indicates a D1 receptors-mediated action of L-Dopa. Expand
Modulatory effects of L-DOPA on D2 dopamine receptors in rat striatum, measured using in vivo microdialysis and PET
TLDR
It is likely that L-DOPA sensitising effect on striatal D2 receptors, as confirmed by PET, may implicate striato-pallidal neurones, hence a reduced GABA-ergic output in the projection area of anaesthetised rats. Expand
Role of opiates in striatal D-1 dopamine receptor supersensitivity induced by chronic L-dopa treatment.
TLDR
The data suggest that prolonged indirect activation of striatal opiate receptors and their consequent desensitization could be among the causes of the hyperactivity of D-1 dopamine receptors that follows chronic L-dopa treatment. Expand
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function
TLDR
Results indicated that the D3 receptors participated in both dyskinesia and the therapeutic action of levodopa, and that partial agonists may normalize D3 receptor function and correct side effects of levidopa therapy in patients with Parkinson disease. Expand
Dopaminergic denervation enhances susceptibility to hydroxyl radicals in rat neostriatum
TLDR
It is concluded that DA innervation normally suppresses •OH formation, and that the antiparkinsonian drug L-DOPA has no effect or slightly reduces•OH formation in the neostriatum, probably by virtue of its bathing the system of newly formed •OH. Expand
Comparison of effects of L-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic neurones.
TLDR
It is proposed that systemically administered d-amphet-amine selectively depresses the firing rate of dopamine-containing cells in the substantia nigra zona compacta and adjacent ventral tegmental area of the rat midbrain and that these drugs also slow dopamine cells. Expand
l‐3,4‐Dihydroxyphenylalanine‐Induced Dopamine Release in the Striatum of Intact and 6‐Hydroxydopamine‐Treated Rats: Differential Effects of Monoamine Oxidase A and B Inhibitors
TLDR
A model in which exogenous l‐DOPA elicits enhanced extracellular accumulation of dopamine in the dopamine‐depleted striatum is supported because some transmitter synthesis occurs at nondopaminergic sites and the dopamine terminals that normally take up and catabolize this pool of transmitter are absent. Expand
Early L-DOPA treatment initially retards but later enhances dopamine receptor supersensitivity following unilateral dopamine denervation
TLDR
The findings suggest that the initiation of antiparkinsonian treatment prior to the onset of denervated dopamine receptors supersensitivity in the 6-OHDA model is a valuable strategy to determine if a drug treatment retards or facilitates the development of dopamine receptor supersensitivity. Expand
Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease
TLDR
It is reported, using radioligands selective for the D2 and D3 receptor, that these receptors are independently changed in Parkinson's disease (PD), interesting in light of the development of antiparkinsonian agents that are D3‐preferring agonists. Expand
...
1
2
3
4
5
...